Abstract 59P
Background
BC is a heterogeneous disease with variable clinical outcomes among patients with the same clinical and pathological characteristics, treated with similar treatment. Despite significant improvement in the outcomes, many of them acquire resistance to multiple anticancer drugs, leading to recurrence and /or metastasis. It remains an unmet need to identify robust molecular defects and novel biomarkers to adopt individualized treatment decisions in BC. CGP using next generation sequencing (NGS) provides more druggable gene aberrations at “one go” that includes somatic BRCA (sBRCA), homologous recombinant repair pathway alteration (HRR) and tumor agnostic markers like tumor mutation burden (TMB) and microsatellite instability (MSI) burden.
Methods
140 BC cases at HCG cancer centre were profiled using Illumina TruSight Oncology 500 assay on a NextSeq2000 in an IRB-approved study. The findings from NGS data were discussed in the molecular tumor board (MTB) and recommendations were documented for change in clinical management and follow-up.
Results
Clinically relevant variants were detected in 133/140 BC patients (95%) with actionable mutations in >80% cases with direct impact on therapy and constituted of 47% Tier 1 and 41% Tier 2 mutations. CGP revealed a multitude of genomic alterations such as PI3KCA/AKT/PTEN signalling pathway (32%) in HR+Her2- mBC and ESR1 mutation (7%) in HR+ mBC predictive of resistance to anti-Her2 and endocrine therapy respectively. 22 patients (16%) with sBRCA and HRR pathways alteration treated either with platinum / PARP inhibitors post platinum treatment were found to have partial-to-complete pathological response (pCR). 23 BC patients with high TMB (16%) were initiated on immunotherapy as a single drug or in combination with chemotherapy and are on follow up. The mutation spectrum, HRR pathway alterations and high TMB of triple- negative BC (TNBC) cases revealed a distinctive mutational profile with clinical utility in >95% cases.
Conclusions
Recommending CGP tests at a more appropriate time helps in modifying BC treatment protocol, clinical decisions and provides patients with greater benefit from targeted treatments based on their specific gene alterations and resistance mechanism.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
B.S. Ajaikumar: Financial Interests, Personal and Institutional, Member of Board of Directors, Executive Chairman: HCG. All other authors have declared no conflicts of interest.
Resources from the same session
452P - The relationship between BCG immunotherapy and oxidative stress parameters in patients with non-muscle invasive bladder cancer
Presenter: Mukul Singh
Session: Poster Display
Resources:
Abstract
453P - Palonosetron plus megestrol acetate verses palonosetron plus dexamethasone in preventing moderately emetogenic chemotherapy-induced nausea and vomiting: A randomized, multicenter, crossover, phase II trial
Presenter: Qiaoqi Li
Session: Poster Display
Resources:
Abstract
454P - A multicenter randomized open-label phase II study investigating optimal antiemetic therapy for patients with advanced/recurrent gastric cancer treated with trastuzumab deruxtecan (T-DXd): EN-hance study
Presenter: Akira Ooki
Session: Poster Display
Resources:
Abstract
455P - Assessing model-predicted neurokinin-1 (NK1) receptor occupancy (RO) of netupitant to support efficacy over an extended time period
Presenter: Matti Aapro
Session: Poster Display
Resources:
Abstract
456P - Oxycodone/naloxone in moderate-to-severe cancer pain: A phase III study in China
Presenter: Ping Lu
Session: Poster Display
Resources:
Abstract
457P - Anticoagulation for terminal cancer patients with cancer associated venous thromboembolism
Presenter: Sang Bo Oh
Session: Poster Display
Resources:
Abstract
458P - Association between TSPAN15 and SLC44A2 genetic polymorphisms and venous thromboembolism in cancer patients
Presenter: Alshimaa Al Hanafy
Session: Poster Display
Resources:
Abstract
459P - Association between national health screening program and undertreatment of dyslipidemia in cancer survivors: A cross-sectional study
Presenter: Sujeong Shin
Session: Poster Display
Resources:
Abstract
460P - Group to grow: A systematic review of group-based interventions for post-traumatic growth on cancer patients
Presenter: Dyta William
Session: Poster Display
Resources:
Abstract
461P - A randomized controlled trial of yoga in locally advanced non-small cell lung cancer patients receiving chemoradiotherapy
Presenter: Indranil Khan
Session: Poster Display
Resources:
Abstract